Eglen Medicine Recognized as 'High-Growth Enterprise of the Year' by Securities Times

7Month19Day,The 12th China Venture Capital Forum, hosted by the Securities Times and supported by the China Venture Capital Association Alliance, was grandly held in Zhangjiang, Shanghai.. This selection event invited multiple venture capital institutions and start-up companies to participate. As the annual gathering of the venture capital community, the forum grandly announced "2024China Venture Capital Golden Eagle Award" and "2024The award ceremony for the "New Sprout Award for Chinese Start-up Enterprises" was held.Evergreen Therapeutics, as an industry-leading companyAIEmpowering Clinical R&D: An International Innovative Pharmaceutical Enterprise with Unique CapabilitiesAITechnical platform and highly innovative development potential, standing out from hundreds of participating startups, and winning the "2024Annual High-Growth Enterprise of "China New Venture Award"。

List of High-Growth Companies and Award Plaques for 2024

From2009Since the year, as the information disclosure media managed by the People's Daily and designated by financial regulatory agencies, the Securities Times has successively held eleven sessions of the Venture Capital Golden Eagle Awards and seven sessions of the New Seedling Awards for start-up enterprises. It has witnessed the development and improvement of China's venture capital industry and also the growth of batch after batch of outstanding venture capital institutions and innovative enterprises. This time,After rounds of selection by the expert panel, the final evaluation was completed.10Among the "Annual High-Growth Enterprises," Evergreen Therapeutics and Insilico Medicine were the only two pharmaceutical companies to be honored with this selection.This is authoritative media on Evergreen Therapeutics inAIThe recognition and affirmation of innovation strength and future development potential in the clinical pharmaceuticals field.

Self2019Since its establishment in [Year], Evergreen Therapeutics has consistently adhered to the R&D philosophy of differentiation, efficient clinical practices, and internationalization, leveraging its unique...AITechnology platform, completing the full-process drug development from the synthesis and optimization of new molecules, pharmacological and toxicological predictions, indication expansion, to clinical trials. With rich clinical experience and an international regulatory background, it takes the lead in using self-developed...AIThe platform is engaged in clinical design and clinical development. It not only enables half of its proprietary pipeline to advance efficiently through clinical trials in the United States, but also leverages the team's expertise in clinical regulations and technical platforms to empower other pharmaceutical companies with international drug development needs.

In recent years, Evergreen Therapeutics has gained widespread recognition from government departments, mainstream media, and professional institutions for its scientific research innovation capabilities, efficient transformation of results, and development potential, winning several industry honors and awards. In the future, Evergreen Therapeutics will continue to...“Focus on Clinical Needs, Benefit Patients Worldwide”On a mission to continuously and efficiently develop more innovative therapies for patients worldwide through technological innovation.